All In Biotech

Drug Trial Radar · NCT07711262

Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis

A Randomized, Double-blind, Positive-control and Placebo-controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety in Rupatifen Fumarate Capsules for the Seasonal Allergic Rhinitis Patients

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Aug 18, 2026

Primary completion

Oct 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase Ⅲ randomized, double-blind, active- and placebo-controlled trial aims to assess the efficacy and safety of Rupatifen Fumarate Capsules for seasonal allergic rhinitis. Eligible participants will be randomized to Rupatifen Fumarate Capsules, Rupatadine Fumarate Tablets (active comparator), or matching placebo. All treatments are administered once daily at a consistent time with a 24 ± 2-hour interval between doses for 2 consecutive weeks.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • Rupatifen Fumarate CapsulesDrug

    Oral administration, one capsule once daily for 14 consecutive days

  • Rupatadine Fumarate TabletsDrug

    Oral administration, one tablet once daily for 14 consecutive days

  • Rupatifen Fumarate Capsules PlaceboDrug

    Oral administration, one capsule once daily for 14 consecutive days

  • Rupatadine Fumarate Tablets PlaceboDrug

    Oral administration, one tablet once daily for 14 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the average reflective Total Nasal Symptom Score (rTNSS) during the treatment periodTime frame: From baseline (Day 1 pre-dose) through Day 15 (end of treatment)

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Emergency General Hospital

    Beijing, China · Recruiting

  • Peking University Third Hospital

    Beijing, China · Recruiting

  • Tianjin People's Hospital

    Tianjin, China · Recruiting

  • The No.2 Hospital of Baoding

    Baoding, Hebei, China · Recruiting

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China · Recruiting

  • Hebei General Hospital

    Shijiazhuang, Hebei, China · Recruiting

  • Hebei Provincial Hospital of Traditional Chinese Medicine

    Shijiazhuang, Hebei, China · Recruiting

  • The First Affiliated Hospital of Hebei North University

    Zhangjiakou, Hebei, China · Recruiting

  • Baogang Hospital of Inner Mongolia

    Baotou, Inner Mongolia, China · Recruiting

  • Baotou Central Hospital

    Baotou, Inner Mongolia, China · Recruiting

  • Chifeng Municipal Hospital

    Chifeng, Inner Mongolia, China · Recruiting

  • The First People's Hospital of Yinchuan

    Yinchuan, Ningxia, China · Recruiting

  • Shandong Second Provincial General Hospital

    Jinan, Shandong, China · Recruiting

  • Linfen Central Hospital

    Linfen, Shanxi, China · Recruiting

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Recruiting

  • Second hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Recruiting

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.